Tracon Pharmaceuticals, Inc. (TCON): Ronald L Shazer , Chief Medical Officer of Tracon Pharmaceuticals, Inc. sold 1,003 shares on Jun 3, 2016. The Insider selling transaction was reported by the company on Jun 7, 2016 to the Securities and Exchange Commission. The shares were sold at $7.48 per share for a total value of $7,502.44 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Oct 19, 2015, Super V3 Investment Limi Jafco (10% owner) sold 1,500 shares at $9.90 per share price.On Sep 22, 2015, H Casey Logan (Chief Business Officer) sold 5,000 shares at $17.34 per share price.Also, On Sep 22, 2015, Charles Theuer (President and CEO) sold 10,000 shares at $17.34 per share price.On Feb 5, 2015, Scott D Sandell (10% owner) purchased 500,000 shares at $10.00 per share price.
TRACON Pharmaceuticals Inc: On Friday, Jun 3, 2016 heightened volatility was witnessed in TRACON Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $7.48 and hit $7.76 on the upside , eventually ending the session at $7.42, with a gain of 8.32% or 0.57 points. The heightened volatility saw the trading volume jump to 1,36,525 shares. The 52-week high of the share price is $18.35 and the company has a market cap of $91 M . The 52-week low of the share price is at $5.88.
TRACON Pharmaceuticals Inc. (TRACON) is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer age-related macular degeneration (AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate TRC105 is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. Its other anti-endoglin antibody is TRC205 which is in preclinical development for the treatment of fibrotic diseases. The Company is also developing TRC102 a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.